LOINC Code 83055-4: PD-L1 by clone 28-8 Immune stain Ql (Tiss)
83055-4 is a LOINC code used to identify PD-L1 by clone 28-8 Immune stain Ql (Tiss) in laboratory and clinical observation data. You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges. LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Programmed cell death ligand 1 by clone 28-8. It is commonly used with the system or sample type Tiss.
What is this code?
LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Programmed cell death ligand 1 by clone 28-8. It is commonly used with the system or sample type Tiss.
When is it used?
- Used in lab systems, EHRs, and clinical data exchange.
- May identify a test, observation, survey item, or clinical document request rather than a diagnosis.
- Status: ACTIVE
- Order vs observation: Both
- Method: Immune stain
What it does not mean
- The code identifies the observation or test, not the actual result.
Key facts
- PD-L1 by clone 28-8 [Presence] in Tissue by Immune stain
- Programmed cell death ligand 1 by clone 28-8
- This term should be used to report the presence of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone 28-8. Patients with certain cancers, such as non-squamous non small cell lung cancer (NSCLC) or melanoma, whose tumors are positive for PD-L1 by 28-8 may be eligible for anti-programmed death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [83053-9]. A tumor with >= 1% staining by 28-8 is considered PD-L1 positive. This term was created for, but is not limited in use to, the Dako PD-L1 28-8 pharmDx test kit, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with certain cancers are eligible for nivolumab therapy.
- B7 homolog 1; B7-H1; CD274; Cluster of differentiation 274; i; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; PDL1; PD-L1; PD-L1 by 28-8; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified
Where you may see this code
You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges.
Common synonyms
Frequently asked questions
About this content
This page is prepared by HealthAssure's clinical team using official coding standards from LOINC. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.